Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Apr;18(2):153-156.
doi: 10.1007/s12311-018-0986-6.

Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?

Affiliations
Editorial

Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?

Mario Manto et al. Cerebellum. 2019 Apr.

Abstract

Anti-GAD65 antibodies (anti-GAD65 Abs) are associated with cerebellar ataxia (CA). The significance of anti-GAD65 Abs has been a focus of debates. Since GAD65 is intracellularly located and associated with type 1 diabetes mellitus and different clinical neurological phenotypes such as CA, stiff-person syndrome, and epilepsy, some researchers have argued that anti-GAD65 Abs have no pathogenic roles. On the other hand, recent physiological studies in vitro and in vivo have elucidated that binding of GAD65 by anti-GAD65 Abs elicits loss of GAD65 functions pertaining GABA release with an epitope dependence, leading to the development of CA. Internalization of autoantibodies has been also clarified. These studies provide substantial evidence of the pathogenesis of anti-GAD65 Abs in CA. We also discuss methodological problems in the identification of anti-GAD65 Abs.

Keywords: Anti-GAD65 antibodies; Cerebellar ataxia; Cerebellum; Glutamic acid decarboxylase 65.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, Andres C, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies. Study of 14 patients. Arch Neurol. 2001;58:225–230. doi: 10.1001/archneur.58.2.225. - DOI - PubMed
    1. Hadjivassiliou M, Martindale J, Shanmugarajah P, Grünewald RA, Sarrigiannis PG, Beauchamp N, Garrard K, Warburton R, Sanders DS, Friend D, Duty S, Taylor J, Hoggard N. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J Neurol Neurosurg Psychiatry. 2017;88:301–309. doi: 10.1136/jnnp-2016-314863. - DOI - PubMed
    1. Arińo H, Gresa-Arribas N, Blanco Y, Martínez-Hernández E, Sabater L, Petit-Pedrol M, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies. Immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71:1009–1016. doi: 10.1001/jamaneurol.2014.1011. - DOI - PMC - PubMed
    1. Mitoma H, Adhikari K, Aeschlimann D, Chattopadhyay P, Hadjivassiliou M, Hampe CS, et al. Consensus paper: neuroimmune mechanisms of cerebellar ataxias. Cerebellum. 2016;15:2313–2332. doi: 10.1007/s12311-015-0664-x. - DOI - PMC - PubMed
    1. Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14. doi: 10.1186/s40673-015-0034-y. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources